Company news

Akebia Therapeutics, Inc. news in 2021

Akebia Therapeutics, Inc.'s news releases, calls and decks from 2021, newest first.

View company

Akebia Therapeutics Announces Participation in Upcoming Investor Conferences

November 23, 2021

Akebia Therapeutics to Present at Jefferies London Healthcare Conference

November 14, 2021

Akebia Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Company Milestones

November 3, 2021

Akebia Therapeutics Appoints Ron Frieson, Healthcare Operations Leader, to Board of Directors

October 31, 2021

Akebia Announces Otsuka's Submission of Initial Marketing Authorization Application to the European Medicines Agency for Vadadustat for the Treatment of Patients with Anemia due to Chronic Kidney Disease

October 28, 2021

Akebia Therapeutics to Report Third Quarter 2021 Financial Results and Highlight Recent Company Milestones

October 25, 2021

Statement from Akebia Therapeutics Regarding Litigation Against Centers for Medicare & Medicaid Services and the U.S. Department of Health and Human Services

October 24, 2021

Akebia Announces Vadadustat Efficacy and Safety Data to be Presented at American Society of Nephrology Kidney Week 2021

October 17, 2021

Akebia Therapeutics Announces September 2021 Investor Conference Schedule

August 31, 2021

Akebia Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Company Milestones

August 4, 2021

Akebia Therapeutics to Report Second Quarter 2021 Financial Results and Discuss Recent Business Highlights

July 25, 2021

Akebia Therapeutics Announces Presentations at ERA-EDTA Virtual Congress 2021

June 2, 2021

Akebia and Otsuka Announce FDA Acceptance for Filing of New Drug Application for Vadadustat for the Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis and Not on Dialysis

May 31, 2021

Akebia Reports First Quarter 2021 Financial Results and Highlights Recent Company Milestones

May 9, 2021

New England Journal of Medicine Publishes Results of Global Phase 3 Clinical Program of Vadadustat for the Treatment of Anemia Due to Chronic Kidney Disease

April 27, 2021

Akebia Therapeutics to Report First Quarter 2021 Financial Results and Discuss Recent Business Highlights

April 27, 2021

Akebia Therapeutics to Present at 20th Annual Needham Virtual Healthcare Conference

April 11, 2021

Akebia Submits New Drug Application (NDA) to the FDA for Vadadustat for the Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis and Not on Dialysis

March 29, 2021

Akebia Therapeutics Announces Poster Presentations and Educational Symposium at National Kidney Foundation 2021 Virtual Spring Clinical Meetings

March 24, 2021

Akebia Therapeutics Announces Approval for Additional Indication of Riona® (ferric citrate hydrate) for the Treatment of Iron Deficiency Anemia in Adult Patients in Japan

March 23, 2021

Akebia Therapeutics Celebrates World Kidney Day and National Kidney Month

March 10, 2021

Akebia Therapeutics to Present at H.C. Wainwright Global Life Sciences Conference

March 1, 2021

Akebia Reports Fourth Quarter and Full-Year 2020 Financial Results and Provides Business Updates

February 24, 2021

Akebia Therapeutics Appoints LeAnne M. Zumwalt, Dialysis Industry Leader, to Board of Directors

February 17, 2021

Akebia Therapeutics to Report Fourth Quarter and Full-Year 2020 Financial Results and Discuss Recent Business Highlights

February 7, 2021

Calls in 2021

Decks in 2021